Listing 1 - 2 of 2 |
Sort by
|
Choose an application
This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease.
Medicine --- small bowel neuroendocrine tumours --- pancreatic neuroendocrine tumours --- liver metastases --- midgut --- meta-analysis --- neuroendocrine tumors --- carcinoid heart disease --- carcinoid syndrome --- somatostatin analogues --- metastases --- multidisciplinary --- management --- outcome --- grading --- staging --- neuroendocrine neoplasms --- chemotherapy --- temozolomide --- metronomic treatment --- second-line --- NOTCH --- cancer-driven genes --- mutational mechanism --- germline mutations --- small cell lung carcinoma --- pancreatic NET --- small bowel NET --- medullary thyroid carcinoma --- malignant castration-resistant prostatic cells --- quality performance indicators --- QPIs --- cancer care --- neuroendocrine tumour --- NETs --- modified Delphi --- CommNETs --- pancreatic neuroendocrine neoplasms --- neuroendocrine tumor --- long-term functional outcomes --- pancreatectomy --- diabetes mellitus --- pancreatic exocrine insufficiency --- body mass index --- parenchyma-sparing surgery --- neuroendocrine tumours --- curative surgery --- resection --- follow-up --- guidelines --- relapse --- recurrence --- risk factor --- mixed non-neuroendocrine neuroendocrine neoplasms --- MiNENs --- mixed adeno-neuroendocrine carcinoma --- MANEC --- 2017 WHO classification --- 2019 WHO classification --- small bowel neuroendocrine tumours --- pancreatic neuroendocrine tumours --- liver metastases --- midgut --- meta-analysis --- neuroendocrine tumors --- carcinoid heart disease --- carcinoid syndrome --- somatostatin analogues --- metastases --- multidisciplinary --- management --- outcome --- grading --- staging --- neuroendocrine neoplasms --- chemotherapy --- temozolomide --- metronomic treatment --- second-line --- NOTCH --- cancer-driven genes --- mutational mechanism --- germline mutations --- small cell lung carcinoma --- pancreatic NET --- small bowel NET --- medullary thyroid carcinoma --- malignant castration-resistant prostatic cells --- quality performance indicators --- QPIs --- cancer care --- neuroendocrine tumour --- NETs --- modified Delphi --- CommNETs --- pancreatic neuroendocrine neoplasms --- neuroendocrine tumor --- long-term functional outcomes --- pancreatectomy --- diabetes mellitus --- pancreatic exocrine insufficiency --- body mass index --- parenchyma-sparing surgery --- neuroendocrine tumours --- curative surgery --- resection --- follow-up --- guidelines --- relapse --- recurrence --- risk factor --- mixed non-neuroendocrine neuroendocrine neoplasms --- MiNENs --- mixed adeno-neuroendocrine carcinoma --- MANEC --- 2017 WHO classification --- 2019 WHO classification
Choose an application
This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease.
small bowel neuroendocrine tumours --- pancreatic neuroendocrine tumours --- liver metastases --- midgut --- meta-analysis --- neuroendocrine tumors --- carcinoid heart disease --- carcinoid syndrome --- somatostatin analogues --- metastases --- multidisciplinary --- management --- outcome --- grading --- staging --- neuroendocrine neoplasms --- chemotherapy --- temozolomide --- metronomic treatment --- second-line --- NOTCH --- cancer-driven genes --- mutational mechanism --- germline mutations --- small cell lung carcinoma --- pancreatic NET --- small bowel NET --- medullary thyroid carcinoma --- malignant castration-resistant prostatic cells --- quality performance indicators --- QPIs --- cancer care --- neuroendocrine tumour --- NETs --- modified Delphi --- CommNETs --- pancreatic neuroendocrine neoplasms --- neuroendocrine tumor --- long-term functional outcomes --- pancreatectomy --- diabetes mellitus --- pancreatic exocrine insufficiency --- body mass index --- parenchyma-sparing surgery --- neuroendocrine tumours --- curative surgery --- resection --- follow-up --- guidelines --- relapse --- recurrence --- risk factor --- mixed non-neuroendocrine neuroendocrine neoplasms --- MiNENs --- mixed adeno-neuroendocrine carcinoma --- MANEC --- 2017 WHO classification --- 2019 WHO classification
Listing 1 - 2 of 2 |
Sort by
|